ATE528648T1 - Verfahren zum nachweis antikörper-herstellender zellen - Google Patents

Verfahren zum nachweis antikörper-herstellender zellen

Info

Publication number
ATE528648T1
ATE528648T1 AT03778577T AT03778577T ATE528648T1 AT E528648 T1 ATE528648 T1 AT E528648T1 AT 03778577 T AT03778577 T AT 03778577T AT 03778577 T AT03778577 T AT 03778577T AT E528648 T1 ATE528648 T1 AT E528648T1
Authority
AT
Austria
Prior art keywords
antibody
producing
producing cells
antibody producing
cells
Prior art date
Application number
AT03778577T
Other languages
English (en)
Inventor
Derek Thomas Brown
Lisa Butler
Karen Dorothy Cromie
Meryn Ruth Griffiths
Alastair D G Lawson
Daniel John Lightwood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228188A external-priority patent/GB0228188D0/en
Priority claimed from GB0319587A external-priority patent/GB0319587D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE528648T1 publication Critical patent/ATE528648T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03778577T 2002-12-03 2003-12-01 Verfahren zum nachweis antikörper-herstellender zellen ATE528648T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228188A GB0228188D0 (en) 2002-12-03 2002-12-03 Biological products
GB0319587A GB0319587D0 (en) 2003-08-20 2003-08-20 Biological products
PCT/GB2003/005254 WO2004051268A1 (en) 2002-12-03 2003-12-01 Assay for identifying antibody producing cells

Publications (1)

Publication Number Publication Date
ATE528648T1 true ATE528648T1 (de) 2011-10-15

Family

ID=32472152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778577T ATE528648T1 (de) 2002-12-03 2003-12-01 Verfahren zum nachweis antikörper-herstellender zellen

Country Status (9)

Country Link
US (1) US7993864B2 (de)
EP (1) EP1570267B1 (de)
JP (1) JP4603894B2 (de)
AT (1) ATE528648T1 (de)
AU (1) AU2003285578B2 (de)
CA (1) CA2507004A1 (de)
ES (1) ES2374068T3 (de)
PT (1) PT1570267E (de)
WO (1) WO2004051268A1 (de)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658498A1 (de) * 2003-08-20 2006-05-24 Celltech R & D Limited Verfahren zur gewinnung von antikörpern
EP1658500B1 (de) 2003-08-20 2012-04-18 UCB Pharma, S.A. Verfahren zur gewinnung von antikörpern
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
EP2343363A1 (de) * 2005-07-01 2011-07-13 John Schrader Verfahren zur Isolierung von Zellen und Erzeugung monoklonaler Antikörper unter Verwendung einer Einzel-Epitop Mehrfach-Färbung
ATE546160T1 (de) 2005-09-14 2012-03-15 Ucb Pharma Sa Antikörper-kammpolymer-konjugat
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
WO2007122823A1 (ja) * 2006-04-20 2007-11-01 Jichi Medical University ベクター産生型腫瘍標的細胞
EP2021463B1 (de) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Anbauverfahren zum erhalten einer klonpopulation von antigenspezifischen b-zellen
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2557090A3 (de) 2006-12-19 2013-05-29 Ablynx N.V. Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
KR101570702B1 (ko) * 2007-03-13 2015-11-23 유니버시티 오브 취리히 단일클론 인간 종양-특이적 항체
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
GB0721752D0 (en) * 2007-11-06 2007-12-19 Univ Southampton Configurable electronic device and method
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
EP2947097A1 (de) 2008-04-07 2015-11-25 Ablynx N.V. Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2285833B1 (de) 2008-05-16 2014-12-17 Ablynx N.V. Gegen cxcr4 und andere gpcr gerichtete aminosäuresequenzen sowie verbindungen damit
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
CN107011434B (zh) 2008-12-19 2021-02-19 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
PE20120211A1 (es) 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
EP2401294B1 (de) 2009-02-25 2018-09-05 UCB Biopharma SPRL Verfahren zur herstellung von antikörpern
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2487249B1 (de) * 2009-10-09 2018-06-13 Kawasaki Jukogyo Kabushiki Kaisha Verfahren und vorrichtung zur unterscheidung undifferenzierter pluripotenter stammzellen sowie automatisches kulturverfahren und vorrichtung dafür
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
EP2506874A1 (de) 2009-12-01 2012-10-10 Ablynx N.V. Von-willebrand-faktor-spezifische bindemittel und ihre verwendung
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
US9625464B2 (en) 2010-03-25 2017-04-18 National University Corporation University Of Toyama Fluorescent probe for plasma cell identification and isolation, and plasma cell identification or isolation method using the probe
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP2571901B1 (de) 2010-05-20 2019-01-02 Ablynx N.V. Biologische stoffe im zusammenhang mit her3
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
TWI619730B (zh) 2010-11-08 2018-04-01 Ablynx Nv 趨化細胞素受體結合多肽
WO2012095662A1 (en) 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
EP2691418A1 (de) 2011-03-28 2014-02-05 Ablynx N.V. Bispezifische gegen cxcr4 gerichtete variable immglobulineinzeldomänen
WO2012133572A1 (ja) * 2011-03-30 2012-10-04 国立大学法人富山大学 形質細胞または形質芽細胞の選択方法、目的抗原特異的な抗体の製造方法、新規モノクローナル抗体
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3363813A1 (de) 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
DK2974737T3 (da) 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
WO2013034579A1 (en) 2011-09-05 2013-03-14 Rheinische Friedrich-Wilhelms-Universität Bonn Biosynthetic gene cluster for the production of peptide/protein analogues
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
US8921055B2 (en) 2012-10-30 2014-12-30 Berkeley Lights, Inc. Detecting cells secreting a protein of interest
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3303390A1 (de) 2015-05-27 2018-04-11 UCB Biopharma SPRL Verfahren zur behandlung neurologischer erkrankungen
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
KR20240156437A (ko) 2015-10-27 2024-10-29 유씨비 바이오파마 에스알엘 항-il-17a/f 항체를 사용한 치료 방법
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
US9395367B1 (en) 2016-02-29 2016-07-19 Rarecyte, Inc. Method to identify antigen-specific B cells for antibody development
US9442113B1 (en) 2016-02-29 2016-09-13 Rarecyte, Inc. Method to identify antigen-specific immune cells for therapeutic development
EP3469069A4 (de) 2016-06-10 2020-01-22 Kota Biotherapeutics, LLC Zusammensetzungen und verfahren mit b-lymphozyt-zell-linie, die ein unterschiedliches membranimmunglobulin als sekretiertes immunglobulin exprimiert, und zytolysefunktion
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN112236451A (zh) * 2017-10-26 2021-01-15 Essenlix公司 引起性传播疾病的细菌和免疫t细胞检测
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP7565219B2 (ja) 2018-06-18 2024-10-10 ユーシービー バイオファルマ エスアールエル がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト
AR117653A1 (es) 2018-10-16 2021-08-25 UCB Biopharma SRL Método para tratamiento de miastenia grave
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
PE20211867A1 (es) 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
KR102800844B1 (ko) 2019-02-18 2025-04-29 가부시키가이샤 에누비 켄코우겡큐쇼 세포의 선발 방법, 핵산의 제조 방법, 재조합 세포의 제조 방법, 목적 물질의 제조 방법, 의약 조성물의 제조 방법, 및 시약
TWI884171B (zh) 2019-09-30 2025-05-21 日商東京應化工業股份有限公司 分泌物產生細胞的篩選方法、及分泌物產生細胞的篩選套組
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
ES2975410T3 (es) 2020-02-13 2024-07-05 UCB Biopharma SRL Anticuerpos biespecíficos que se unen a HVEM y CD9
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
AU2021361083A1 (en) 2020-10-13 2023-05-11 Almirall, S.A. Bispecific molecules and methods of treatment using the same
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45
CA3197465A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
CN116802211A (zh) 2020-12-07 2023-09-22 Ucb生物制药有限责任公司 针对白介素-22的抗体
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
US20250277023A1 (en) 2021-04-22 2025-09-04 Guangdong Fapon Biopharma Inc. Multifunctional bispecific fusion polypeptide
IL308100A (en) 2021-05-03 2023-12-01 UCB Biopharma SRL Antibodies
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
JP2025539866A (ja) 2022-11-28 2025-12-09 ユーシービー バイオファルマ エスアールエル 線維筋痛症の処置
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
TW202547865A (zh) 2024-05-17 2025-12-16 比利時商Ｕｃｂ生物製藥公司 具有il-11結合特異性的抗體
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
AU1436188A (en) 1987-04-08 1988-10-13 Synbiotics Corp. Method for the early selection of anti-idiotype antibody internal images
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE69332884T2 (de) 1992-10-21 2003-11-20 Stefan Miltenyi Direkte auswahl von zellen durch ein aussheidungsprodukt
JP4540846B2 (ja) 1998-04-30 2010-09-08 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 所望の生物学的特性を与えるクローンを発現ライブラリーから同定する新規方法
ATE437366T1 (de) 1998-05-11 2009-08-15 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen- spezifischen t-zellen
JP2000304750A (ja) * 1999-04-16 2000-11-02 Fuji Photo Film Co Ltd 発光標識イムノアッセイ及びその分析要素
ATE324590T1 (de) * 2000-01-31 2006-05-15 Univ Emory System und verfahren für immunologische assays
AUPR177400A0 (en) * 2000-11-29 2000-12-21 Cancerprobe Pty Ltd Probes for identifying cancer-specific antigens
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
US20040240687A1 (en) * 2003-05-30 2004-12-02 Graetz Michael L. Flat panel speaker
GB0412973D0 (en) 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells

Also Published As

Publication number Publication date
EP1570267B1 (de) 2011-10-12
ES2374068T3 (es) 2012-02-13
JP4603894B2 (ja) 2010-12-22
PT1570267E (pt) 2012-01-03
AU2003285578A1 (en) 2004-06-23
CA2507004A1 (en) 2004-06-17
EP1570267A1 (de) 2005-09-07
US7993864B2 (en) 2011-08-09
US20060148012A1 (en) 2006-07-06
AU2003285578B2 (en) 2010-07-15
JP2006509217A (ja) 2006-03-16
WO2004051268A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
DE60141844D1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
DK1322960T4 (da) Allergen-mikroarrayassay
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
DE60307645D1 (de) Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
DE602006011756D1 (de) Komplexformierungs- und -trennungsverfahren
GB0900151D0 (en) rapid bioluminescence detection system
SE0001670D0 (sv) Mass-spectrometry-based biosensor
CN107367616A (zh) 一种前列腺特异性抗原检测试剂与试剂盒
DK0755517T3 (da) Fremgangsmåde til detektion af tilstedeværelse af en Mycobacterium-art og et kit og antistoffer til anvendelse i denne
SG164389A1 (en) Detection of a therapeutic antibody in an experimental animal
MX2008000282A (es) Anticuerpos monoclonales, lineas celulares de hibridomas, metodos y kits para la deteccion de fitasa.
EP2023139A4 (de) Immuntestverfahren und -chip
DE602006018432D1 (de) Antigennachweis
NO20052553D0 (no) Cobalaminanalyse.
ATE533053T1 (de) Nicht-elispot-test
DE602005024254D1 (de)
DK1879029T3 (da) Immuneftervisningskit i forbindelse med neuroglobinenzym samt anvendelse heraf
ATE391914T1 (de) Assay
Kergaravat et al. Magneto immunofluorescence assay for diagnosis of celiac disease
RU2007140911A (ru) Способ выявления антигенов и антител в иммуноферментном анализе
ATE440968T1 (de) Verfahren zur diagnostizierung von aspirinunverträglichkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties